368 related articles for article (PubMed ID: 29559475)
1. Germline Lysine-Specific Demethylase 1 (
Wei X; Calvo-Vidal MN; Chen S; Wu G; Revuelta MV; Sun J; Zhang J; Walsh MF; Nichols KE; Joseph V; Snyder C; Vachon CM; McKay JD; Wang SP; Jayabalan DS; Jacobs LM; Becirovic D; Waller RG; Artomov M; Viale A; Patel J; Phillip J; Chen-Kiang S; Curtin K; Salama M; Atanackovic D; Niesvizky R; Landgren O; Slager SL; Godley LA; Churpek J; Garber JE; Anderson KC; Daly MJ; Roeder RG; Dumontet C; Lynch HT; Mullighan CG; Camp NJ; Offit K; Klein RJ; Yu H; Cerchietti L; Lipkin SM
Cancer Res; 2018 May; 78(10):2747-2759. PubMed ID: 29559475
[TBL] [Abstract][Full Text] [Related]
2. Association of a dominantly inherited hyperphosphorylated paraprotein target with sporadic and familial multiple myeloma and monoclonal gammopathy of undetermined significance: a case-control study.
Grass S; Preuss KD; Ahlgrimm M; Fadle N; Regitz E; Pfoehler C; Murawski N; Pfreundschuh M
Lancet Oncol; 2009 Oct; 10(10):950-6. PubMed ID: 19767238
[TBL] [Abstract][Full Text] [Related]
3. Expression, Purification, and Biochemical Analysis of the LSD1/KDM1A Histone Demethylase.
Laurent B; Shi Y
Methods Enzymol; 2016; 573():241-59. PubMed ID: 27372756
[TBL] [Abstract][Full Text] [Related]
4. Lysine-Specific Demethylase 1 (LSD1/KDM1A) Is a Novel Target Gene of c-Myc.
Nagasaka M; Tsuzuki K; Ozeki Y; Tokugawa M; Ohoka N; Inoue Y; Hayashi H
Biol Pharm Bull; 2019; 42(3):481-488. PubMed ID: 30828079
[TBL] [Abstract][Full Text] [Related]
5. Lysine-specific demethylase (LSD1/KDM1A) and MYCN cooperatively repress tumor suppressor genes in neuroblastoma.
Amente S; Milazzo G; Sorrentino MC; Ambrosio S; Di Palo G; Lania L; Perini G; Majello B
Oncotarget; 2015 Jun; 6(16):14572-83. PubMed ID: 26062444
[TBL] [Abstract][Full Text] [Related]
6. A comprehensive review of lysine-specific demethylase 1 and its roles in cancer.
Hosseini A; Minucci S
Epigenomics; 2017 Aug; 9(8):1123-1142. PubMed ID: 28699367
[TBL] [Abstract][Full Text] [Related]
7. Familial occurrence of multiple myeloma and monoclonal gammopathy of undetermined significance in 5 siblings.
Bizzaro N; Pasini P
Haematologica; 1990; 75(1):58-63. PubMed ID: 2110928
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic Targeting of KDM1A/LSD1 in Ewing Sarcoma with SP-2509 Engages the Endoplasmic Reticulum Stress Response.
Pishas KI; Drenberg CD; Taslim C; Theisen ER; Johnson KM; Saund RS; Pop IL; Crompton BD; Lawlor ER; Tirode F; Mora J; Delattre O; Beckerle MC; Callen DF; Sharma S; Lessnick SL
Mol Cancer Ther; 2018 Sep; 17(9):1902-1916. PubMed ID: 29997151
[TBL] [Abstract][Full Text] [Related]
9. Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cells.
Fiskus W; Sharma S; Shah B; Portier BP; Devaraj SG; Liu K; Iyer SP; Bearss D; Bhalla KN
Leukemia; 2014 Nov; 28(11):2155-64. PubMed ID: 24699304
[TBL] [Abstract][Full Text] [Related]
10. Risk of Japanese carriers of hyperphosphorylated paratarg-7, the first autosomal-dominantly inherited risk factor for hematological neoplasms, to develop monoclonal gammopathy of undetermined significance and multiple myeloma.
Grass S; Iida S; Wikowicz A; Preuss KD; Inagaki A; Shimizu K; Ziepert M; Ueda R; Pfreundschuh M
Cancer Sci; 2011 Mar; 102(3):565-8. PubMed ID: 21205072
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological Inhibition of the Histone Lysine Demethylase KDM1A Suppresses the Growth of Multiple Acute Myeloid Leukemia Subtypes.
McGrath JP; Williamson KE; Balasubramanian S; Odate S; Arora S; Hatton C; Edwards TM; O'Brien T; Magnuson S; Stokoe D; Daniels DL; Bryant BM; Trojer P
Cancer Res; 2016 Apr; 76(7):1975-88. PubMed ID: 26837761
[TBL] [Abstract][Full Text] [Related]
12. MiR-137 functions as a tumor suppressor in neuroblastoma by downregulating KDM1A.
Althoff K; Beckers A; Odersky A; Mestdagh P; Köster J; Bray IM; Bryan K; Vandesompele J; Speleman F; Stallings RL; Schramm A; Eggert A; Sprüssel A; Schulte JH
Int J Cancer; 2013 Sep; 133(5):1064-73. PubMed ID: 23400681
[TBL] [Abstract][Full Text] [Related]
13. Cell of Origin and Genetic Alterations in the Pathogenesis of Multiple Myeloma.
Barwick BG; Gupta VA; Vertino PM; Boise LH
Front Immunol; 2019; 10():1121. PubMed ID: 31231360
[TBL] [Abstract][Full Text] [Related]
14. From MGUS to Multiple Myeloma, a Paradigm for Clonal Evolution of Premalignant Cells.
van Nieuwenhuijzen N; Spaan I; Raymakers R; Peperzak V
Cancer Res; 2018 May; 78(10):2449-2456. PubMed ID: 29703720
[TBL] [Abstract][Full Text] [Related]
15. Oncogenic role and target properties of the lysine-specific demethylase KDM1A in chronic lymphocytic leukemia.
Jiang Q; Stachelscheid J; Bloehdorn J; Pacholewska A; Aszyk C; Grotenhuijs F; Müller T; Onder O; Wagle P; Herling CD; Kleppe M; Wang Z; Coombes KR; Robrecht S; Dalvi PS; Plosnita B; Mayer P; Abruzzo LV; Altmüller J; Gathof B; Persigehl T; Fischer K; Jebaraj B; Rienhoff HY; Ecker R; Zhao Y; Bruns CJ; Stilgenbauer S; Elenitoba-Johnson K; Hallek M; Schweiger MR; Odenthal M; Vasyutina E; Herling M
Blood; 2023 Jul; 142(1):44-61. PubMed ID: 37023372
[TBL] [Abstract][Full Text] [Related]
16. Kdm1a promotes SCLC progression by transcriptionally silencing the tumor suppressor Rest.
Jin Y; Ma D; Gramyk T; Guo C; Fang R; Ji H; Shi YG
Biochem Biophys Res Commun; 2019 Jul; 515(1):214-221. PubMed ID: 31146914
[TBL] [Abstract][Full Text] [Related]
17. Targeting KDM1A attenuates Wnt/β-catenin signaling pathway to eliminate sorafenib-resistant stem-like cells in hepatocellular carcinoma.
Huang M; Chen C; Geng J; Han D; Wang T; Xie T; Wang L; Wang Y; Wang C; Lei Z; Chu X
Cancer Lett; 2017 Jul; 398():12-21. PubMed ID: 28377178
[TBL] [Abstract][Full Text] [Related]
18. The spectrum of somatic mutations in monoclonal gammopathy of undetermined significance indicates a less complex genomic landscape than that in multiple myeloma.
Mikulasova A; Wardell CP; Murison A; Boyle EM; Jackson GH; Smetana J; Kufova Z; Pour L; Sandecka V; Almasi M; Vsianska P; Gregora E; Kuglik P; Hajek R; Davies FE; Morgan GJ; Walker BA
Haematologica; 2017 Sep; 102(9):1617-1625. PubMed ID: 28550183
[TBL] [Abstract][Full Text] [Related]
19. KDM1A microenvironment, its oncogenic potential, and therapeutic significance.
Ismail T; Lee HK; Kim C; Kwon T; Park TJ; Lee HS
Epigenetics Chromatin; 2018 Jun; 11(1):33. PubMed ID: 29921310
[TBL] [Abstract][Full Text] [Related]
20. KDM1A inhibition is effective in reducing stemness and treating triple negative breast cancer.
Zhou M; Venkata PP; Viswanadhapalli S; Palacios B; Alejo S; Chen Y; He Y; Pratap UP; Liu J; Zou Y; Lai Z; Suzuki T; Brenner AJ; Tekmal RR; Vadlamudi RK; Sareddy GR
Breast Cancer Res Treat; 2021 Jan; 185(2):343-357. PubMed ID: 33057995
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
